Sanofi’s $9.1B Blueprint Medicines acquisition boosts rare disease and oncology pipeline

Sanofi completed the $9.1 billion acquisition of Blueprint Medicines, gaining access to the approved KIT inhibitor Ayvakit for systemic mastocytosis and a robust pipeline in immunological diseases and oncology. Blueprint's targeted tyrosine kinase inhibitors and AI-driven compound library enhance Sanofi’s precision medicine capabilities. The deal supports Sanofi's expansion in rare diseases and oncology with mid- and late-stage assets, including next-gen KIT inhibitors in development. Blueprint is projected to generate over $700 million in sales in 2025 from Ayvakit.